본문 바로가기

Mesenchymal Stem Cells and Extracellular Vesicles Derived from Canine Adipose Tissue Ameliorates Inflammation, Skin Barrier Function and Pruritus by Reducing JAK/STAT Signaling in Atopic Dermatitis

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
피인용
Web of Science 30Scopus 32
FWCI (Scopus)
2.04
JCR IF
JCR 2021 6.208
ISSN
1661-6596

저자

  1. Kim, Sung Youl제1저자GNG CELL Co Ltd, R&D Ctr, 122 Unjung Ro, Seongnam Si 13466, South Korea
  2. Yoon, Tae HongGNG CELL Co Ltd, R&D Ctr, 122 Unjung Ro, Seongnam Si 13466, South Korea
  3. Na, JungtaeSogang Univ, Dept Life Sci, 35 Baekbeom Ro, Seoul 04107, South Korea
  4. Yi, Seong JoonKyungpook Natl Univ, Coll Vet Med, Dept Vet Anat, 80 Daehak Ro, Daegu 41566, South Korea
  5. Jin, YunseokKyungpook Natl Univ, Coll Vet Med, Dept Vet Internal Med, 80 Daehak Ro, Daegu 41566, South Korea
  6. Kim, MinjiKyungpook Natl Univ, Coll Vet Med, Dept Vet Internal Med, 80 Daehak Ro, Daegu 41566, South Korea
  7. Oh, Tae-Ho교신저자Kyungpook Natl Univ, Coll Vet Med, Dept Vet Internal Med, 80 Daehak Ro, Daegu 41566, South Korea
  8. 정태욱교신저자Pusan Natl Univ, R&D Ctr, Natl Clin Res Ctr Korean Med, JIN BioCell Co Ltd,Korean Med Hosp, 20 Geumo Ro, Yangsan Si 50612, South Korea

초록

© 2022 by the authors. Licensee MDPI, Basel, Switzerland.Canine atopic dermatitis (AD) is a common chronic inflammatory skin disorder resulting from imbalance between T lymphocytes. Current canine AD treatments use immunomodulatory drugs, but some of the dogs have limitations that do not respond to standard treatment, or relapse after a period of time. Thus, the purpose of this study was to evaluate the immunomodulatory effect of mesenchymal stem cells derived from canine adipose tissue (cASCs) and cASCs-derived extracellular vesicles (cASC-EVs) on AD. First, we isolated and characterized cASCs and cASCs-EVs to use for the improvement of canine atopic dermatitis. Here, we investigated the effect of cASCs or cASC-EVs on DNCB-induced AD in mice, before using for canine AD. Interestingly, we found that cASCs and cASC-EVs improved AD-like dermatitis, and markedly decreased levels of serum IgE, (49.6%, p = 0.002 and 32.1%, p = 0.016 respectively) epidermal inflammatory cytokines and chemokines, such as IL-4 (32%, p = 0.197 and 44%, p = 0.094 respectively), IL-13 (47.4%, p = 0.163, and 50.0%, p = 0.039 respectively), IL-31 (64.3%, p = 0.030 and 76.2%, p = 0.016 respectively), RANTES (66.7%, p = 0.002 and 55.6%, p = 0.007) and TARC (64%, p = 0.016 and 86%, p = 0.010 respectively). In addition, cASCs or cASC-EVs promoted skin barrier repair by restoring transepidermal water loss, enhancing stratum corneum hydration and upregulating the expression levels of epidermal differentiation proteins. Moreover, cASCs or cASC-EVs reduced IL-31/TRPA1-mediated pruritus and activation of JAK/STAT signaling pathway. Taken together, these results suggest the potential of cASCs or cASC-EVs for the treatment of chronic inflammation and damaged skin barrier in AD or canine AD.

키워드

atopic dermatitiscanineextracellular vesicleinflammationmesenchymal stem cellpruritusskin barrier functionALLERGIC AIRWAY INFLAMMATIONCONTACT HYPERSENSITIVITYBONE-MARROWEFFICACYDISEASEBLOODDOGSACTIVATIONEXPRESSIONTGF-BETA-1

식별자

Scopus EID
2-s2.0-85129039168
WoS UID
000794761600001